No Data
Express News | hubei biocause pharmaceutical: china best life insurance's original insurance premium income in January-October 2024 is approximately 31.386 billion yuan
Tianmao Group: Report for the third quarter of 2024
A-share insurance sector rises, hubei biocause pharmaceutical surges more than 7%.
On October 23rd, Biocause Pharmaceutical rose by over 7%, Kaisa Jiayun Technology Inc., Qitian Technology Group, Shenzhen Kingdom Sci-Tech, Jiangxi Tianli Technology, Inc., Ping An Insurance, Xin Hua Insurance and other companies followed the upward trend.
Tianmao Group: Tianmao Group\'s performance forecast for the first three quarters of 2024
hubei biocause pharmaceutical (000627.SZ) issued a profit warning, expecting a net loss of 0.315 billion yuan to 0.345 billion yuan in the first three quarters.
hubei biocause pharmaceutical (000627.SZ) released the performance forecast for the first three quarters of 2024, expecting the attributable net profit for the first three quarters to be above...
hubei biocause pharmaceutical (000627.SZ): It is expected to incur a loss of 0.315 billion yuan-0.345 billion yuan in the first three quarters.
Geelonghui October 14th | Hubei Biocause Pharmaceutical (000627.SZ) announced the performance forecast for the first three quarters of 2024, with a net income loss attributable to the shareholders of the listed company of 0.345 billion yuan to 0.315 billion yuan, a loss of 212.9954 million yuan in the same period of the previous year; the net income loss after deducting non-recurring gains and losses is 0.344 billion yuan to 0.314 billion yuan, a loss of 209.636 million yuan in the same period of the previous year; basic earnings per share loss of 0.070 yuan/share to 0.064 yuan/share. In the third quarter of 2024, the net income attributable to the shareholders of the listed company was profitable 20 million yuan–
No Data
No Data